Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2007-10-30
2007-10-30
Canella, Karen A. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S138100, C424S141100, C424S155100, C530S387100, C530S387700, C530S202000, C530S388800
Reexamination Certificate
active
10447331
ABSTRACT:
The present application describes a method for making antibodies which can be used for cancer diagnosis or therapy. The application also discloses a method for identifying an antigen which is differentially expressed on the surface of two or more distinct cell populations. The application additionally describes human antibodies directed against decay accelerating factor (DAF), as well as therapeutic compositions comprising such antibodies. Moreover, the application discloses a method of treating lung cancer with antibodies directed against DAF.
REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5565332 (1996-10-01), Hoogenboom et al.
patent: 5695945 (1997-12-01), Tsuji
patent: 5733743 (1998-03-01), Johnson et al.
patent: 5763224 (1998-06-01), Caras et al.
patent: 2003/0129677 (2003-07-01), Martens et al.
patent: 2007/0104717 (2007-05-01), Pienta et al.
patent: 1 157 041 (2005-06-01), None
patent: WO 86/07062 (1986-12-01), None
patent: WO 90/04415 (1990-05-01), None
patent: 94/26787 (1994-11-01), None
patent: WO 94/26787 (1994-11-01), None
patent: 95/15982 (1995-06-01), None
patent: WO 95/15982 (1995-06-01), None
patent: 97/02479 (1997-01-01), None
patent: WO 97/02479 (1997-01-01), None
patent: WO 97/04801 (1997-02-01), None
patent: 98/15833 (1998-04-01), None
patent: 98/16827 (1998-04-01), None
patent: WO 98/15833 (1998-04-01), None
patent: WO 98/16827 (1998-04-01), None
patent: WO 98/39659 (1998-09-01), None
patent: 98/50431 (1998-11-01), None
patent: WO 98/50431 (1998-11-01), None
patent: WO 99/43800 (1999-09-01), None
patent: 99/56129 (1999-11-01), None
patent: WO 99/56129 (1999-11-01), None
Clark (Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man, 1993, p. 1.
Vollmers et al (Cancer, 1995, vol. 76, pp. 550-558).
Hensel et al (Cancer Research, 1999, vol. 59, pp. 5299-5306).
Varsano et al (Clin Exp Immunol, 1998, 113, pp. 173-182).
Simpson et al, Am J Pathology, 1997, vol. 151, pp. 1455-1467.
Aviv et al., “Purification of Biologically Active Globin Messenger RNA by Chromatography on Oligothymidylic Acid-Cellulose”Proc. Natl. Acad. Sci. USA69(6):1408-1412 (Jun. 1972).
Baker et al., “Humanization of an anti-mucin antibody for breast and ovarian cancer therapy”Advances in Experimental Medicine&Biology353:61-82 (1994).
Barratt-Boyes, S., “Making the most of mucin: a novel target for tumor immunotherapy”Cancer Immunology, Immunotherapy43(3):142-151 (Nov. 1996).
Cai and Garen, “A melanoma-specific VHantibody cloned from a fusion phage library of a vaccinated melanoma patient”Proc. Natl. Acad. Sci. USA93(13):6280-6285 (Jun. 25, 1996).
Cai and Garen, “Anti-melanoma antibodies from melanoma patients immunized with genentically modified autologous tumor cells: selection of specific antibodies from single-chain Fv fusion phage libraries”Proc. Natl. Acad. Sci. USA92(14):6537-6541 (Jul. 3, 1995).
Cai and Garen, “Comparison of fusion phage libraries displaying VHor single-chain Fv antibody fragments derived from the antibody repertoire of a vaccinated melanoma patient as a source of melanoma-specific targeting molecules”Proc. Natl. Acad. Sci. USA94(17):9261-9266 (Aug. 19, 1997).
Carter and Ridgway, “The next generation bispecific antibodies through domain interface engineering”Antibody Engineering II: New Technology, Application, and Commercialization, International Business Communications, Inc., Chapter 2.2, vol. 1:115-130 (1997).
Carter et al., “High levelEscherichia coliexpression and production of a bivalent humanized antibody fragment”Bio/Technology10:163-167 (1992).
Carter et al., “Humanization of an anti-p185HER2antibody for human cancer therapy”Proc. Natl. Acad. Sci.89:4285-4289 (May 1992).
Chee et al., “Accessing genetic information with high-density DNA arrays”Science274(5287):610-614 (Oct. 25, 1996).
Cheung et al., “Decay-accelerating factor protects human tumor cells from complement-mediated cytotoxicity in vitro”Journal of Clinical Investigation81(4):1122-1128 (Apr. 1988).
Chirgwin et al., “Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease”Biochemistry18(24):5294-5299 (Nov. 27, 1979).
Christensen and Leslie, “Quantitative measurement of Fc receptor activity on human peripheral blood monocytes and the monocyte-like cell line, U937, by laser flow cytometry”Journal of Immunological Methods132(2):211-219 (Sep. 14, 1990).
Couto et al., “Engineering of antibodies for breast cancer therapy: construction of chimeric and humanized versions of the murine monoclonal antibody BrE-3”Advances in Experimental Medicine&Biology353:55-59 (1994).
Couto et al., “Humanization of KC4G3, an Anti-Human Carcinoma Antibody”Hybridoma13:215-219 (1994).
de Kruif et al., “Rapid selection of cell subpopulation-specific human monoclonal antibodies from a synthetic phage antibody library”Proc. Natl. Acad. Sci. USA92(9):3938-3942 (Apr. 25, 1995).
DeRisi et al., “Use of a cDNA microarray to analyse gene expression patterns in human cancer”Nature Genetics14(4):457-460 (Dec. 1996).
Griffiths et al., “Isolation of High Affinity Human Antibodies Directly From Large Synthetic Repertoires”EMBO Journal13:3245-3260 (1994).
Hamann et al., “The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF)”Journal of Experimental Medicine184(3):1185-1189 (Sep. 1, 1996).
Hara et al., “A monoclonal antibody against human decay-accelerating factor (DAF, CD55), D17, which lacks reactivity with semen-DAF”Immunology Letters37(2-3):145-152 (Aug. 1993).
Hara et al., “Levels of complement regulatory proteins, CD35 (CR1), CD46 (MCP) and CD55 (DAF) in human haematological malignancies”British Journal of Haematology82(2):368-373 (Oct. 1992).
Hayes, D., “Should we treat HER, too?”Journal of Clinical Oncology14(3):697-699 (Mar. 1996).
Henderikx et al., “Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma”Cancer Research58(19):4324-4332 (Oct. 1, 1998).
Hensel et al., “Characterization of glycosylphosphatidylinositol-linked molecule CD55/decay-accelerating factor as the receptor for antibody SC-1-induced apoptosis”Cancer Research59(20):5299-5306 (Oct. 15, 1999).
Hibi et al., “Serial analysis of gene expression in non-small cell lung cancer”Cancer Research58(24):5690-5694 (Dec. 15, 1998).
Huls et al., “A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments”Nature Biotechnology17(3):276-281 (Mar. 1999).
Kaminski et al., “Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma”Journal of Clinical Oncology14(7):1974-1981 (Jul. 1996).
Kaminski et al., “Radioimmunotherapy of B-cell Lymphoma with (131I) Anti-B1 (Anti-CD20) Antibody”New England J. of Medicine329:459-465 (1993).
Koretz et al., “Decay-accelerating factor (DAF, CD55) in normal colorectal mucosa, adenomas and carcinomas”British Journal of Cancer66(5):810-814 (Nov. 1992).
Liang and Pardee, “Recent advances in differential display”Current Opinion in Immunology7(2):274-280 (Apr. 1995).
Lublin et al., “Biosynthesis and Glycosylation of the Human Complement Regulatory Protein Decay-Accelerating Factor”Journal of Immunology137(5):1629-1635 (1986).
Maloney et al., “IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma”Blood90(6):2188-2195 (Sep. 15, 1997).
Marks et al., “By-passing immunization: human antibodies from V-gene libraries displayed on phage”J. Mol. Biol. 222:581-597 (1991).
Marks et al., “Human antibody fragments specific for human blood group antigens from a phage di
Carter Paul J.
Ridgway John B.
Canella Karen A.
Dreger, Esq. Ginger R.
Genentech Inc.
Heller Ehrman LLP
Svoboda, Esq. Craig
LandOfFree
Antibodies for cancer therapy and diagnosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies for cancer therapy and diagnosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies for cancer therapy and diagnosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3903102